Enveric Biosciences
EB-003 · Novel Psychedelic Compound · Depression / Anxiety
Company Overview
Enveric Biosciences is a patient-focused pharmaceutical company developing novel psychedelic-inspired medicines. Their lead asset EB-003 is a next-generation psychedelic compound in preclinical development for depression and anxiety. EB-002 (formerly EB-373, a psilocin prodrug) was renamed and out-licensed to MycoMedica Life Sciences for up to $62M in milestone payments. The company completed a 1:12 reverse stock split in October 2025. ⚠ FINANCIAL DISTRESS: As of Q3 2025, cash is approximately $3.8M.
Pipeline
| Drug / Compound | Stage | Indication |
|---|---|---|
EB-003 Novel psychedelic compound | Preclinical | Depression / Anxiety |
EB-002 Psilocin prodrug (formerly EB-373 / EVM201) | Preclinical | Depression / Anxiety |
Key Financials
- Cash Position
- ~$3.8M
- Burn Rate
- ~$2M/quarter
- Last Reported
- Q3 2025
Financial data is approximate. Always verify with official SEC filings.
Upcoming Catalysts
- 2026EB-003 IND-enabling studies progress updateRegulatory
Recent News
- 2025-10Enveric completes 1:12 reverse stock split; EB-373 renamed EB-002 and out-licensed to MycoMedica for up to $62M
News items are manually curated from public company press releases.
External Links
Looking for psychedelic therapy?
Browse our directory of 700+ verified ketamine and psychedelic therapy clinics across 49 states. Find providers near you who offer ketamine and psychedelic-assisted therapy.
Disclaimer: This page is for informational purposes only and does not constitute investment, medical, or financial advice. Pipeline status, financial figures, and catalyst dates are approximate and based on publicly available information as of 2026-02-25. Always consult official company filings and a qualified financial advisor before making investment decisions.